Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

MacroGenics Signs Another Lucrative DART Deal with Janssen For $75m Up Front

Executive Summary

Janssen Biotech Inc. apparently likes what it's seen so far from the first bi-specific antibody that it licensed from MacroGenics Inc., because the Johnson & Johnson subsidiary obtained rights to a second asset from the Rockville, Maryland-based firm's Dual Affinity Re-Targeting (DART) platform.


Related Content

MacroGenics Regains DART Asset As Takeda Narrows Focus
MacroGenics, Merck Seize Gastric Cancer Opportunity With Margetuximab, Keytruda Combo
Janssen, MacroGenics sign potential $575m+ licensing deal
BioNotebook: Two key fires at Retrophin, NewLink; three deals and three financings
Takeda signs option deal for MacroGenics bi-specific antibody
BioNotebook Deals and Data: Zosano/Novo, MacroGenics/Servier, Regulus/Sanofi, Seattle Genetics/Takeda, Sarepta
Gilead targets MacroGenics in potential $1B+ DART deal
Servier buys into MacroGenics' Phase I anticancer MAb
MacroGenics boosted by broad DART antibody deal with Boehringer


Related Companies